Samalizumab

Samalizumab is a humanized monoclonal antibody designed for oncology indications. Samalizumab is a recombinant humanized monoclonal antibody that targets the immunoregulatory protein CD200. Results from a Phase I study indicated the drug has potential for use in treating cancers including chronic lymphocytic leukemia.

Samalizumab was developed by Alexion Pharmaceuticals.